|
BLACK SABBATH’s IOMMI Says He Will Probably Have To Get Cancer …
BLABBERMOUTH.NET He said there was a 30 percent chance of it going away, but I was probably going to have this for life. Now I get treatments to keep it from spreading. So every six weeks I go in for an infusion of Rituximab, which is one of the four ingredients when … |
Scotsman |
Non-Hodgkin lymphoma survival doubles since early 1970s
Medical Xpress These vast improvements are largely thanks to better treatments – particularly the drug rituximab, which Cancer Research UK scientists laid the groundwork for with their early work into the immune system – and earlier diagnosis linked to improved … New treatments see blood cancer survival rates upScotsman |
21-day R-CHOP regimen remains standard in diffuse B-cell lymphomasHealioA 14-day regimen of rituximab plus CHOP failed to demonstrate improvement compared with the standard 21-day regimen in a cohort of patients with previously B-cell lymphomas, accord…
|
It’s all in what you say and how you say it
Lexology (registration) Subsequently, scientists found that rituximab could be used to treat another blood cancer, i.e., chronic lymphocytic leukemia (CLL), and Biogen filed a patent application based on this finding. This patent issued as US Patent No. 7,682,612, with claim … |
Cancer Research UK (press release) |
Non-Hodgkin lymphoma survival doubles since early 1970s
Cancer Research UK (press release) These vast improvements are largely thanks to better treatments – particularly the drug rituximab, which Cancer Research UK scientists laid the groundwork for with their early work into the immune system – and earlier diagnosis linked to improved … New treatments see blood cancer survival rates upScotsman |
Biologic sequences with abatacept more cost effective than rituximab in …HealioBiologic sequences that included abatacept appeared more efficient and cost effective compared with those using rituximab as treatment for rheumatoid arthritis patients wh…
OncLivePfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin – OncLiveOncLiveThe phase III study explored inotuzumab ozogamicin plus rituximab specifically as a treatment for patients with relapsed or refractory CD22-positive, aggressive non-Ho…
 Times LIVE |
Pfizer drug fails in Phase III NHL trial
PharmaTimes In the trial, inotuzumab ozogamicin was administered once-a-month schedule in combination with Roche’s Rituxan (rituximab) and compared with either Teva’s Treanda (bendamustine) plus rituximab or Eli Lilly’s Gemzar (gemcitabine) plus rituximab). Pfizer discontinues phase III study of inotuzumab ozogamicin in relapsed or …pharmabiz.com Correction: Pfizer-Study Halted storyYahoo! New Zealand News Non-Hodgkin Rx Trial HalteddailyRx PMLiVE –FierceBiotech –Medical Daily all 11 news articles » |
|
Cell Therapeutics receives German Federal Joint Committee’s final benefit …
pharmabiz.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri –rituximab to gemcitabine-rituximab in patients who have … |
|
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or …
MarketWatch (press release) In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab and compared with an active comparator arm (investigator’s choice of bendamustine plus rituximab or gemcitabine plus rituximab). During a … Pfizer halts study of non-Hodgkin’s lymphoma drugBusinessweek Pfizer (PFE) says it’s discontinuing Phase 3 studies on its investigational …Seeking Alpha |